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Background: Rifaximin is an antibiotic, acting locally in the gastrointestinal tract, which may 
exist in different crystal as well as amorphous forms. The current marketed rifaximin formula-
tion contains polymorph alpha, the systemic bioavailability of which is very limited. This study 
compared the pharmacokinetics of this formulation with those of the amorphous form.
Methods: Amorphous rifaximin was specifically prepared for the study and formulated as the 
marketed product. Two doses (200 mg and 400 mg) of both formulations were given to two 
groups of 12 healthy volunteers of either sex according to a single-blind, randomized, two-
treatment, single-dose, two-period, cross-over design. Plasma and urine samples were collected 
at preset times (for 24 hours or 48 hours, respectively) after dosing, and assayed for rifaximin 
concentrations by high-performance liquid chromatography-mass spectrometry.
Results: For both dose levels, peak plasma concentration, area under the concentration-time 
curve, and cumulative urinary excretion were significantly higher after administration of 
amorphous rifaximin than rifaximin-α. Ninety percent confidence intervals for peak plasma 
concentration, area under the concentration-time curve, and urinary excretion ratios were largely 
outside the upper limit of the accepted (0.80–1.25) range, indicating higher systemic bioavail-
ability of the amorphous rifaximin. The few adverse events recorded were not serious and not 
related to the study medications.
Conclusion: Rifaximin-α, a crystal polymorph, does differ from the amorphous form, the lat-
ter being systemically more bioavailable. In this regard, care must be taken when using – as a 
medicinal product – a formulation containing even small amounts of amorphous form, which 
may alter the peculiar pharmacologic properties of this poorly absorbed antibiotic.
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Introduction
Locally acting drugs are applied locally and are assumed to exert their effect at the 
site of application.1,2 Examples include, amongst others, orally administered formula-
tions designed to achieve a local effect within the gastrointestinal tract. In these cases, 
a systemic action, if any, would be considered undesirable and could actually elicit 
adverse effects.1,2
Through variations in local and/or systemic bioavailability, changes in formulation 
or dosage form may influence the efficacy and/or safety of locally acting medicines. 
In addition to formulation, the physicochemical characteristics of the active ingredient 
are also relevant to local and/or systemic bioavailability. Indeed, the chemical struc-
ture of the molecule, its polar surface area, pH partition, particle size, salt form, drug 
complexation, as well as crystal forms or amorphous state can all affect dissolution 
and absorption rates.3,4 While most of the above parameters have been extensively 
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studied for locally acting compounds, crystal polymorphism 
has often been overlooked. 
Po lymorph i sm,  wh ich  i s  ve ry  common  in 
pharmaceuticals,5–8 is the ability of a molecule to assemble 
into multiple crystal structures. Different polymorphs have 
different arrangements of atoms within the unit cell, and this 
can quite often have a remarkable impact on the physico-
chemical properties of the crystallized compound. 
Different polymorphs of a drug can display different 
chemicophysical properties, including stability and reactiv-
ity, dissolution rate and solubility, which can affect pharma-
cokinetics (PKs) and pharmacodynamics (PDs).5,7 Relevant 
examples of the impact of polymorphism on systemic bio-
availability have been previously reported.9–12 In extreme 
cases, a polymorph can even be ineffective, as occurred with 
polymorph II of ritonavir.13 
In contrast with polymorphs, amorphous forms consist 
of disordered molecular arrangements and do not display 
three-dimensional crystalline lattices.14 In general, compared 
with crystalline polymorphs, amorphous forms tend to have 
a higher dissolution rate and solubility, which may increase 
the rate and extent of their oral absorption.15
Rifaximin (4-deoxy-4′-methylpyrido[1′,2′-1,2]imidazo 
[5,4-c]rifamycin SV) is a synthetic derivative of rifamycin, 
with very low gastrointestinal absorption, but still displaying 
a broad spectrum of antibacterial activity.16–18 Being virtually 
nonabsorbed, its gastrointestinal bioavailability is high, with 
fecal concentrations largely exceeding minimum inhibitory 
concentrations against pathogenic enterobacteria, while its 
limited impact on extragastrointestinal sites minimizes the 
risk of antimicrobial resistance and systemic adverse events.19 
With appreciation of the pathogenic role of gut flora in sev-
eral gastrointestinal diseases, the use of rifaximin has been 
extended from gastrointestinal infections to hepatic encephal-
opathy, small intestine bacterial overgrowth (SIBO), inflam-
matory bowel disease, and colonic diverticular disease.19,20
According to the European Pharmacopoeia, rifaximin 
shows crystal polymorphism,21 and several polymorphs (α, 
β, γ, δ, ε) have been described.22 In vitro studies show differ-
ent dissolution and solubility rates for these polymorphs, and 
in vivo investigations in dogs found different PK patterns, 
with δ and γ polymorphs displaying the highest systemic 
bioavailability.22
Previous PK studies in healthy volunteers and patients 
with inflammatory bowel disease or intestinal infections 
showed minimal absorption of rifaximin after single and 
repeated doses.20 Of note, these studies were performed 
with the rifaximin product marketed before the discovery 
of rifaximin polymorphism, while the current formulation 
contains only polymorph-α,23 which is widely recognized 
as a poorly absorbed antibiotic.20,24–27
Preclinical studies have shown that polymorphs α and 
β of rifaximin are the least absorbed ones. In vitro dissolu-
tion tests suggested also that the PK behavior of amorphous 
rifaximin is similar to that of γ polymorph, thus implying a 
higher systemic bioavailability than polymorph-α.22 Indeed, 
preliminary animal studies have shown that this is the case 
(Viscomi, unpublished observations).
Generic formulations of rifaximin are available in some 
countries. In a previous paper,28 we compared the PKs of a 
generic rifaximin formulation with those of the branded prod-
uct (the latter containing only polymorph-α) and found that 
most PK parameters were significantly higher after admin-
istration of generic rifaximin. In particular, the differences 
for the highest concentration achieved in plasma (C
max
), area 
under the concentration-time curve (AUC), and cumulative 
urinary excretion between the generic formulation and the 
branded product ranged from 165% to 345%. X-ray power 
diffraction analysis of the generic formulation showed the 
presence of both rifaximin-α and amorphous rifaximin, 
which we thought could have contributed to the increased 
systemic bioavailability of the generic formulation.28 Since 
the key feature of this broad-spectrum antibiotic is to be 
poorly absorbable, the increased absorption could well have 
clinical consequences, especially in long-term use.
The present investigation was therefore carried out to 
prove (or disprove) our hypothesis that the presence of amor-
phous rifaximin is responsible for the increased systemic 
absorption. To this end, we prepared ad hoc an amorphous 
form of rifaximin, formulated as film-coated tablets, using the 
same composition and manufacturing procedure employed 
to produce the reference branded product, and compared its 
plasma PKs with those of polymorph-α in healthy volun-
teers. Since data concerning the systemic bioavailability of 
amorphous rifaximin in humans are lacking, this study will 
also bridge this gap.
Materials and methods
Volunteers
Twenty-four healthy Caucasian adult volunteers of either sex 
and aged 18–55 years participated in this study. At the time 
of enrolment, they were informed of the purpose, methods, 
and potential hazards of the study, and were requested to sign 
their written informed consent. They were also informed of 
the ability to withdraw from the study at any time. The clinical 
evaluations performed to assess the health status of volunteers 
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(both before and after participation in the study) included 
medical history, physical examination, body mass index, vital 
signs (heart rate, systolic and diastolic blood pressure, body 
temperature), electrocardiography, and laboratory investiga-
tions. The results of clinical evaluations were documented 
in individual case report forms. Women were screened for 
β-human chorionic gonadotropin to rule out pregnancy, and 
were requested to use contraception throughout the study 
period. Exclusion criteria included body mass index 18 
or 30 kg/m2, positive urinary drug screening, positive tests 
for human immunodeficiency virus or hepatitis B/C, history 
of major diseases, allergies, intolerance to any ingredients in 
the study drugs, use of medicinal products within 4 weeks of 
starting the study, history of alcohol or drug abuse, drinking 
excessive amounts of beverages containing caffeine or wine 
(0.5 L/day) or spirits (50 mL/day), and abnormal diet or 
eating habits. The volunteers were requested to report any 
abnormality occurring during and after the study.
Design of study
The study was performed in accordance with a single-blind, 
randomized, two-treatment, single-dose, two-period, cross-
over design, with a washout period of 7 days. It was approved 
by the ethics committee of Canton Ticino and Swissmedic 
(Switzerland), and was conducted in accordance with Interna-
tional Conference on Harmonisation guidelines for Good Clini-
cal Practice. The study procedures were in compliance with the 
Declaration of Helsinki in its last amendment (Seoul 2008).
Since the amorphous rifaximin was being tested in 
humans for the first time, volunteers were allocated to six 
cohorts as a safety measure, in accordance with current 
regulatory recommendations.29,30 Subjects within each 
cohort received the study medication only in the absence of 
unexpected serious adverse events or safety concerns related 
to the study medication in the preceding cohort. A total of 
12 volunteers were allocated to the first four cohorts (three 
subjects each), and received a single 200 mg dose (one tablet) 
of the test drug (amorphous rifaximin) and the reference drug 
(rifaximin polymorph-α; Normix®) on different days accord-
ing to the cross-over design. The remaining 12 volunteers 
were allocated to the last two cohorts (six subjects each), and 
received a single 400 mg dose (2×200 mg tablets) of the test 
drug (amorphous rifaximin) and reference drug (rifaximin 
polymorph-α; Normix®), on different days according to the 
cross-over design. Tablets were administered with 250 mL 
of water at 8 am under fasting conditions. About 4, 8, and 
12 hours after drug intake, a lunch (1,200 kcal), a snack 
(150 kcal), and a dinner (900 kcal) were served, respectively, 
with water ad libitum. After drug intake, subjects were 
requested to drink water in accordance with the following 
schedule: 500 mL (one glass of 125 mL approximately every 
hour) of plain mineral water at room temperature during each 
of the 4-hour intervals from drug administration time until 
12 hours after dosing, and then ad libitum until the end of 
urine collection (ie, 48 hours post-dosing).
Ten milliliter venous blood samples were collected into 
tubes containing sodium heparin at preset time intervals of 0 
(predosing) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours 
post-dosing and kept on ice. Plasma was separated from blood 
within 20 minutes by centrifugation at 2,000 g for 10 minutes 
at 4°C. Each plasma sample was split into two aliquots and 
stored at -80°C±10°C. Urine was collected predosing and at 
intervals of 0–4, 4–8, 8–12, 12–24, 24–48 hours post-dosing 
into weighed flasks and refrigerated at 4°C–6°C. The weight 
of each urine fraction was recorded, and a 100 mL sample was 
split into two aliquots and stored at -20°C±5°C.
Preparation and characterization  
of amorphous rifaximin
Amorphous rifaximin was prepared in a GPCG 60 fluid bed 
dryer (Glatt, Ramsey, NJ, USA), equipped with a 1.8 mm 
spraying nozzle. Forty kg of rifaximin-α were charged and 
added with 457.2 L of 96% ethanol (v/v). The suspension was 
stirred continuously until complete dissolution of rifaximin. 
The ethanol solution was sprayed into the fluid bed with a 
pressure of 1–1.5 bar through the nozzle under a flow of 
warm air. At the end of the spraying phase, the solid rifaximin 
powder was further dried to remove the excess solvent and 
then characterized by X-ray power diffraction.31
X-ray powder diffraction analysis 
X-ray powder diffraction data were collected on a Panalyti-
cal X’Pert automated diffractometer in a Bragg-Brentano 
geometry, equipped with a graphite monochromator. The Cu 
anode was used as an X-ray source at 40 kV and 40 mA. Data 
were collected at room temperature, start angle 2q 1/4 3″, stop 
angle 2q 1/4 30″. The instrument was configured with 1/2″ 
divergence and 0.1 mm receiving slits, respectively. Samples, 
stored in stoppered glass bottles, were prepared immediately 
before analysis, avoiding manipulation as much as possible 
to reduce the risk of water uptake.
Preparation of amorphous rifaximin 
tablets and dissolution test
Amorphous rifaximin was used to formulate a single 
batch of 200 mg film-coated tablets, according to the same 
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composition and manufacturing procedure employed to pro-
duce Normix®.32 The dissolution test was performed accord-
ing to the European Pharmacopoeia,33 dissolving each tablet 
in 900 mL of aqueous solution (phosphate buffer at pH 7.4). 
In one set of experiments, sodium lauryl sulfate was added 
to the aqueous solution up to 0.225% (v/v) in order to reach 
the sink conditions.
study medications
The 200 mg film-coated tablets containing amorphous rifaxi-
min were prepared specifically in one batch for this study as 
reported above. The tablets of Normix® employed in the study 
came from the very same batch (number 6188). 
safety evaluation
Volunteers were asked about the occurrence of any adverse 
event after their admission to the clinical unit, both before 
administration of the study drugs and throughout the study 
period, every 4 hours, until their discharge. Radial pulse, 
blood pressure, respiratory rate, and body temperature 
were monitored as vital signs. Clinical evaluations, includ-
ing electrocardiography, blood tests, and urine analysis, 
were performed before enrolment and on the last day of 
the study.
rifaximin assay
Rifaximin concentrations in plasma and urine were 
measured by liquid chromatography-tandem mass spec-
trometry, as previously described;28 the lower limit of 
quantification being 0.5 ng/mL in both biological fluids. 
Each sample was assayed in duplicate. Intra-assay preci-
sion (coefficient of variation, CV%) for the quality control 
samples was 7.2 and mean accuracy ranged from -5.3 to 
-0.3% of the nominal concentration. Interassay precision 
(CV%) was 5.1 and ACC% ranged from -1.1 to +2.3 
of the nominal concentration. No significant interfering 
peaks were found at retention times of rifaximin and of 
internal standard.
Pharmacokinetic evaluations
Noncompartmental analysis was used to calculate the PK 
parameters and was performed using WinNonLin™ soft-
ware (Pharsight, Mountain View, CA, USA). The C
max
, the 
time needed to achieve C
max
, the area under the drug plasma 
concentration-time curve from time 0 to infinity (AUC
0–∞), 
the AUC from time 0 to the time of the last quantifiable 
drug concentration (AUC
0–t
), the plasma drug elimination 
half-life (t
1/2
), and cumulative urinary excretion (Ae
0–48h
) 
were estimated from individual concentration-time curves. 
The first order elimination rate constant was estimated by 
linear regression of time versus the log of drug concentra-
tion using the terminal (log-linear) portion of the curve. 
AUC
0–t
 was calculated by the linear trapezoidal rule. Extrap-
olation to infinity for estimation of AUC
0–∞ was obtained 
by dividing the last quantifiable drug concentration by the 
elimination rate constant and adding this value to AUC
0–t
.34 
The AUC
0–∞ has a considerable (30%) extrapolated por-
tion, which somewhat weakens its value and interpretation. 
However, this parameter is almost always calculated in 
PK studies.
statistical analysis
The results are presented as the mean ± standard error of 
mean. The parametric general linear model for statistical 
analysis included factors accounting for period, sequence, 
and rifaximin formulations. Comparisons for systemic 
bioavailability of the test drug versus the reference drug 
were performed according to European Medicines Agency 
recommendations2 and were defined as the 90% confidence 
intervals of C
max
, AUC
0–∞ (or AUC0–t) and Ae0–48h ratios 
falling within the range of 0.80–1.25. For this purpose, 
C
max
, AUC
0–∞, AUC0–t, and Ae0–48h values were log-natural 
transformed and used to calculate the ratios of each test drug 
over the respective reference drug. Analysis of variance was 
applied to these values, and the residual variance was used in 
Schuirmann’s test35 and for computing the 90% confidence 
intervals of mean ratios.
Results
characterization of amorphous rifaximin
Conversely from rifaximin-α, X-ray diffractogram of the 
amorphous rifaximin preparation showed only two halo-
peaks, with a maximum at 7.75°±0.2°, 14.54°±0.2°, and 
18.33°±0.2° 2θ and the absence of signals of crystallinity 
(Figure 1).
Dissolution test of amorphous rifaximin
Dissolution profiles of rifaximin tablets (with or without 
sodium lauryl sulfate) are shown in Figure 2. To compare 
properly the two profiles, the so-called f1 (difference) and 
f2 (similarity) factors were calculated.36,37 It is generally 
accepted that an f2 value ranging from 50 to 100 indicates 
similarity.36,37 In the absence of sodium lauryl sulfate, f1 
and f2 values were 40.1 and 36.6, respectively, while in the 
presence of 0.225% sodium lauryl sulfate f1 and f2 values 
were 387.4 and 44.5, respectively.
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Demographic characteristics of healthy 
volunteers
The characteristics of healthy subjects, who participated to 
the present studies, are displayed in Table 1.
Plasma and urinary PK profiles
Mean plasma and urinary profiles of the two subgroups (n=12 
each), treated with amorphous rifaximin or rifaximin-α, are 
shown in Figures 3 and 4 for the doses of 200 mg and 400 mg, 
respectively. The respective PK parameters are reported 
in Table 2. In most subjects, the first plasma concentra-
tion of rifaximin was detected at the first blood sampling 
(30 min after dosing) for both rifaximin formulations and 
doses. Concentrations then increased up to peak, which, in 
subjects treated with amorphous rifaximin, was achieved at 
1.96 (range 0.50–12.0) hours and 1.71 (range 0.50–4.0) hours 
for the dose of 200 mg and 400 mg, respectively. In subjects 
receiving rifaximin-α, the peak was reached at 1.04 (range 
0.50–2.0) hours and 1.21 (0.50–4.0) hours after dosing with 
200 mg and 400 mg, respectively.
In subjects treated with 200 mg, rifaximin plasma concen-
trations were lower after administration of rifaximin-α than 
amorphous rifaximin. In this setting, rifaximin concentrations 
were never above the lower limit of quantification in plasma 
samples collected after 8 hours from dosing with rifaximin-α, 
while rifaximin could be detected in plasma up to 16 hours 
from dosing with amorphous rifaximin. Likewise, in vol-
unteers treated with 400 mg, detectable rifaximin plasma 
concentrations were lower after administration of rifaximin-α 
than amorphous rifaximin. With this dose, rifaximin plasma 
concentrations was detected in 2/12 subjects after 12 hours 
and 0/12 after 24 hours from dosing with rifaximin-α, while 
1,500 2,000
1,000
0
1,000
500
C
ou
nt
s
A B
C
ou
nt
s
2θ/degree 2θ/degree
Amorphous rifaximin
Rifaximin-α
0
5 10 15 20 25 30 5 10 15 20 25 30
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rifaximin plasma concentrations could be measured in 10/12 
subjects after 12 hours and 4/12 subjects 24 hours after 
administration of amorphous rifaximin.
After administration of rifaximin-α and amorphous rifaxi-
min at both 200 mg and 400 mg, urine rifaximin concentra-
tions were detected at all collection intervals in all subjects, 
with the exception of one (rifaximin concentration at the 
24–48 hour interval was below the lower limit of quantifica-
tion after 200 mg of rifaximin-α). For both rifaximin forms 
and doses, the highest urine concentration was measured 
at the first interval (0–4 hours), with the exception of three 
volunteers, who displayed the highest concentration at the 
4–8 hour interval.
Rifaximin plasma and urine concentration-time pro-
files and PK parameters showed relevant differences when 
amorphous rifaximin and rifaximin-α were compared. As 
shown in Table 2, most PK parameters were significantly 
higher after administration of amorphous rifaximin than 
rifaximin-α. In particular, the differences for C
max
, AUC
0–t
, 
AUC
0–∞, and Ae0–48h between the amorphous form and 
polymorph-α ranged from 128% to 394% at the dose of 
200 mg, and from 324% to 510% at the dose of 400 mg. 
Moreover, the PK parameters estimated after administra-
tion of amorphous rifaximin 400 mg were from 4.1-fold to 
5.5-fold higher than those obtained with 200 mg, while the 
PK parameters estimated for rifaximin-α 400 mg were from 
2.0-fold to 4.5-fold higher.
The statistical evaluation for cross-over design by means 
of analysis of variance indicated the lack of period and 
sequence effects both for the dose of 200 mg and 400 mg, 
while it showed significant effects of the rifaximin forms 
at both doses, indicating significant differences in systemic 
bioavailability (Table 3). Consistently with this observa-
tion, the 90% confidence interval of the ratios of mean C
max
, 
AUC
0–t
, AUC
0–∞, and Ae0–48h were largely outside the upper 
limit of the 0.80–1.25 interval recommended by the European 
Medicines Agency guideline2 (Table 4). The higher systemic 
bioavailability of amorphous rifaximin 200 mg and 400 mg, 
as compared with rifaximin-α, was also confirmed by the 
Schuirmann’s test.
safety
No serious adverse events occurred during the study. Six 
subjects developed a total of eight adverse events (six mild, 
two moderate). Headache occurred in six subjects (one 
after amorphous rifaximin 200 mg, two after amorphous 
rifaximin 400 mg, and three after rifaximin-α 400 mg). 
Vomiting occurred in two of the above six subjects (one 
Table 1 Demographic characteristics of subjects enrolled in the study (n=12 for each dose tested)
Age (years) Height (cm) Weight (kg) BMI (kg/m2)
200 mg 400 mg 200 mg 400 mg 200 mg 400 mg 200 mg 400 mg
Mean 36.67 37.67 169.25 169.83 67.67 72.75 23.50 25.08
seM 2.46 2.39 2.70 2.14 3.36 3.24 0.78 0.84
cV% 23.27 22.05 5.53 4.46 17.22 15.44 11.55 11.59
Minimum 27.00 21.00 153.00 158.00 52.00 50.00 19.00 20.00
Maximum 51.00 51.00 180.00 186.00 86.00 90.00 27.00 30.00
Abbreviations: BMI, body mass index; CV%, coefficient of variation; SEM, standard error of the mean.
Figure 3 Mean rifaximin concentration-time (A) and cumulative urinary excretion (B) profiles following administration of a single 200 mg dose of amorphous rifaximin or 
rifaximin-α to healthy volunteers. each point or column represents the mean ± standard error of the mean (vertical lines) obtained from 12 subjects.
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after amorphous rifaximin 200 mg and one after rifaximin-α 
400 mg). All adverse events resolved spontaneously, and 
were not considered to be related to the study medications 
upon application of Naranjo et al’s algorithm.38
Discussion
Crystalline polymorphism exhibited by pharmacologically 
active compounds has received widespread attention since the 
early report by Aguiar et al.9 Given that polymorphic forms 
can display different physicochemical properties, which in 
turn may affect chemical processing and/or manufacturing of 
medicinal products, as well as PK/PD profiles,5,8 it has been 
recommended that attention be paid to solid-state forms of 
compounds from the very beginning of their development. 
All long-lived forms of a drug should indeed be revealed as 
early as possible.39,40 Unfortunately, this is not always the 
case, since some compounds, such as rifaximin, had been 
employed in clinical practice for decades before the discovery 
of their polymorphism.
After the case of ritonavir polymorph II,13 regulatory 
authorities started to pay more attention to polymorphism.1,2,41 
Since differences between polymorphs and the amorphous 
form of a drug might even be more relevant than those among 
different crystalline forms, the issue can become very critical 
from a therapeutic standpoint when the amorphous form is 
administered instead of its crystalline counterpart. Provided 
this happens, it might translate into remarkable bioavail-
ability changes, which could affect the efficacy and safety 
of systemic drugs, while impacting mostly on safety when 
locally acting compounds are considered.
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Figure 4 Mean rifaximin concentration-time (A) and cumulative urinary excretion (B) profiles following the administration of a single 400 mg dose amorphous rifaximin or 
rifaximin-α to healthy volunteers. each point or column represents the mean ± standard error of mean (vertical lines) obtained from 12 subjects.
Table 3 analysis of variance for determination of the period, 
sequence, and rifaximin form effects on estimation of cmax, 
aUc0–t and aUc0–∞ after treatment of healthy volunteers with 
amorphous rifaximin and rifaximin-α at a single dose of 200 mg 
(n=12) or 400 mg (n=12)
Period Sequence Form
F p F p F p
200 mg
cmax 1.73 0.2177 0.02 0.8951 36.59 0.0001
aUc0–t 0.28 0.6078 0.26 0.6239 19.52 0.0013
aUc0–∞ 2.12 0.1814 0.06 0.8067 15.82 0.0036
400 mg
cmax 2.70 0.1312 1.55 0.2412 25.30 0.0005
aUc0–t 0.77 0.4020 0.93 0.3564 28.61 0.0003
aUc0–∞ 0.53 0.4843 1.01 0.3373 26.59 0.0004
Abbreviations: cmax, highest concentration achieved in plasma; aUc0–∞, area 
under drug plasma concentration-time curve from time 0 to infinity; AUC0–t, aUc 
from time 0 to time of last quantifiable drug concentration.
Table 2 Mean values of plasma and urine pharmacokinetic 
parameters for rifaximin estimated following administration of 
amorphous rifaximin and rifaximin-α in a single dose of 200 mg 
(n=12) or 400 mg (n=12)
Parameters Amorphous Polymorph-α
200 mg
cmax (ng/ml) 3.70±0.55 1.59±0.35
Tmax (hours) 1.96±0.92 1.04±0.13
aUc0–t (ng/ml⋅h) 11.47±2.34 2.32±0.46
aUc0–∞ (ng/ml⋅h) 16.13±3.14 5.77±0.97
t1/2 (hours) 4.25±1.11 3.07±1.10
ae0–48h (µg) 100.41±20.80 44.06±8.07
400 mg
cmax (ng/ml) 15.01±4.68 3.54±1.12
Tmax (hours) 1.71±0.33 1.21±0.29
aUc0–t (ng/ml⋅h) 63.38±18.39 10.38±3.86
aUc0–∞ (ng/ml⋅h) 68.80±18.61 13.03±4.30
t1/2 (hours) 5.35±0.57 2.23±0.30
ae0–48h (µg) 441.93±121.38 88.34±25.23
Abbreviations: cmax, highest concentration achieved in plasma; Tmax, time needed 
to achieve cmax; aUc0–∞, area under drug plasma concentration-time curve from time 
0 to infinity; AUC0–t, AUC from time 0 to time of last quantifiable drug concentration; 
t1/2, plasma drug elimination half-life; ae0–48h, cumulative urinary excretion.
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Dissolution tests, performed with identical drug formu-
lations containing amorphous rifaximin and polymorph-α, 
respectively, showed that the different water solubility of 
the two rifaximin forms persists in the product formulations, 
even in the presence of sodium lauryl sulfate, a surfactant 
that improves the solubility of rifaximin. Calculation of f1 
(difference) and f2 (similarity) factors demonstrated no simi-
larity between the dissolution profiles of tablets containing 
amorphous rifaximin and rifaximin-α. 
Our PK investigations clearly show that, in comparison 
with polymorph-α, amorphous rifaximin displays higher 
bioavailability, reflected by higher C
max
, AUC, and urinary 
excretion. While this difference was evident with both doses, 
the higher the dose the higher the ratios observed. Since 
rifaximin is usually given at daily doses of 800–1,200 mg, it 
is conceivable that, with the current regimens used in clinical 
practice, systemic absorption of the amorphous form would 
become considerable.
During the 48 hours after its administration, less than 50% 
of rifaximin was excreted in the urine. Rifaximin belongs to 
the rifamycin family, all members of which display consider-
able biliary excretion, reaching minimum inhibitory concen-
trations high enough to allow their use in the treatment of 
biliary infections.42 Although at lower concentrations, also 
rifaximin is excreted through the bile.43 This biliary excre-
tion can account for the amount of rifaximin not recovered 
in the urine.
All the above results agree with previous preclinical find-
ings and, to the best of our knowledge, represent the first evi-
dence of the impact of polymorphism on the bioavailability 
of locally acting oral drugs. In this study, only rifaximin-α 
was investigated, but additional studies should be performed 
to evaluate the PKs of the other polymorphs.
Drug polymorphs occur during the synthesis and 
purification of drugs. The occurrence of a given polymorph 
depends on the conditions of synthesis and crystallization.7,8 
The production process, which must be strictly standardized, 
generally leads to formation of a given polymorph rather 
than the amorphous form of a drug. The increased absorp-
tion of amorphous rifaximin could translate into changes in 
local (ie, intraluminal) bioavailability, which might affect 
clinical efficacy. In addition, the increased systemic bio-
availability of amorphous rifaximin raises some clinically 
relevant concerns. Indeed, for a poorly absorbed antibiotic, 
the antimicrobial activity of which is intended to be exerted 
within the gastrointestinal tract, enhanced systemic absorp-
tion might increase the risk of adverse events.44,45 In the case 
of rifaximin with the polymorph-α contained in the marketed 
formulation, both the short-term and long-term tolerability 
are extremely good,19,25–27 most likely because of the lack of 
systemic absorption. However, after a single 400 mg dose 
of amorphous rifaximin, the C
max
 increased by over 300%. 
When translating these findings to the clinical setting, blood 
levels of rifaximin would be expected to increase even more 
in patients with liver disease, in whom blood concentrations 
of rifaximin-α are already 10–20 times higher, depending on 
disease severity.26,46
Rifaximin is very effective and widely used for the treat-
ment of SIBO.47 The recent appreciation of an association 
between SIBO and functional gut symptoms has renewed 
interest in this mimicry. SIBO indeed can often be present 
in different functional (eg, irritable bowel syndrome, chronic 
constipation, diarrhea) or organic (eg, inflammatory bowel 
disease, celiac disease, diverticular disease) conditions, 
where bacterial proliferation (and consequent minimal 
inflammation) may trigger similar patterns of abdominal 
symptoms. In all these conditions, especially the organic 
ones, rifaximin is used long-term to eradicate pathogenic 
bacteria, reduce the inflammatory response, and achieve 
symptom relief.48,49 As for every drug used on a long-term 
basis, safety, besides efficacy, is of paramount importance. 
Rifaximin-α proved to be extremely safe, even when given 
continuously for 6 months, and its minimal, if any, systemic 
absorption accounts for its favorable adverse event profile, 
which overlaps that of placebo.26 Use of amorphous rifaxi-
min, systemic absorption of which is higher, might not have 
the excellent tolerability of rifaximin-α.
A peculiar and potentially serious adverse event related 
to systemic rifaximin exposure is the development of extra-
gastrointestinal cross-resistance. Rifamycins are pivotal 
drugs for the treatment of Mycobacterium tuberculosis 
infection,42,50 and the activity of rifaximin in the treatment 
of this micro-organism has been carefully investigated. 
Table 4 ratios of mean cmax, aUc0–t, aUc0–∞, and ae0–48h and their 
respective 90% ci estimated after treatment of healthy volunteers 
with amorphous rifaximin (test, T) and rifaximin-α (reference, r) 
at a single dose of 200 mg (n=12) or 400 mg (n=12)
200 mg 400 mg
T/R ratio 90% CI T/R ratio 90% CI
cmax (ng/ml) 2.535 1.92–3.35 3.631 2.28–5.78
aUc0–t (ng/ml⋅h) 6.047 2.89–12.65 6.509 3.45–12.28
aUc0–∞ (ng/ml⋅h) 2.722 1.71–4.33 5.472 3.01–9.95
ae0–48h (µg) 2.155 1.40–3.31 4.728 2.93–7.64
Abbreviations: cmax, highest concentration achieved in plasma; aUc0–∞, area under 
drug plasma concentration-time curve from time 0 to infinity; AUC0–t, aUc from 
time 0 to time of last quantifiable drug concentration; Ae0–48h, cumulative urinary 
excretion; CI, confidence interval.
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Development of resistance to rifaximin in different strains of 
M. tuberculosis isolated from patients with pulmonary and 
renal disease has been studied under stringent conditions.51 
Since the results of these assays showed concentration-de-
pendent subinhibitory effects of rifaximin on mycobacterial 
growth, it was speculated that circulating, albeit very low, 
levels of rifaximin could represent a stimulus for the selection 
of resistant mycobacterial strains.52 However, the evaluation 
of rifaximin and rifampicin minimum inhibitory concen-
trations did not vary in all tested Mycobacterium strains, 
both before and after exposure to rifaximin,51 suggesting 
that rifaximin therapy in gastrointestinal patients harboring 
M. tuberculosis should not represent a hazard to treatment of 
tuberculosis. A 10-year survey53 in Italy showed that myco-
bacterial resistance to rifampicin has remained quite stable 
over time, despite the widespread consumption of rifaximin 
in Italy. It is also worth mentioning that rifampicin is cur-
rently used to eradicate pharyngeal Neisseria meningitidis, 
thereby lowering the potential risk of meningitis.54–56 In this 
setting, the selection of resistant Neisseria mutants could 
theoretically result from use of rifaximin for gastrointes-
tinal infections. Here again, a recent Italian study57 found 
that all meningococci isolated from asymptomatic carriers 
were susceptible to rifampicin, thus arguing against this 
possibility. Overall, while the above-mentioned examples 
of bacterial cross resistance are very unlikely to occur with 
the polymorph-α, taking into account the present data on 
systemic bioavailability, it is conceivable that the risk of 
resistance with amorphous rifaximin might become clini-
cally relevant.
In summary, the results of the present PK investigations 
show different systemic bioavailability of different solid-
state forms of rifaximin. Rifaximin-α, a crystal polymorph, 
does differ from the amorphous form, the latter being sys-
temically bioavailable. In this regard, care must be taken in 
using – as a drug product – a formulation not containing even 
small amounts of the amorphous form, which may alter the 
peculiar pharmacologic properties of this poorly absorbed 
antibiotic.
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